Activity Description:

This grand rounds activity will explore the management and treatment of methadone for pregnant and postpartum patients with opioid use disorder. You'll learn to confidently assess patients, individualize methadone doses, and navigate potential complications. This course will translate into real-world improvements: mothers using less opioids, healthier pregnancies, less severe infant withdrawal symptoms, and stronger family bonds. By participating, you'll not only sharpen your skills but also play a crucial role in improving the lives of mothers, infants, and families impacted by OUD.

Target Audience: 

MDs, DOs, PAs, NPs, CNMWs, CRNAs that provide clinical care to perinatal patients affected by substance use disorders. Other professions are welcome to attend (RNs, Pharmacists, Social Work, etc), but the content is targeted at providers; key topics: initiation of methadone as medication for opioid use disorder (MOUD), continuation of methadone as MOUD, methadone management strategies specific to pregnant patients, methadone management strategies specific to postnatal patients, methadone management in lactating patients, withdrawal management in the setting of methadone initiation, pain control in the setting of methadone management.

Learning Objectives:

At the conclusion of this course, learners should be able to:

1. Identify which perinatal patients with opioid use disorder (OUD) are appropriate to initiate methadone as medication for opioid use disorder (MOUD).
2. Formulate a methadone as MOUD treatment plan for a perinatal patient presenting with OUD to the birthing hospital or clinic
3. Evaluate a perinatal patient's methadone treatment plan and recommend appropriate monitoring and changes based on patient-specific factors.

Faculty:

Presenter: Dr. Kaylin Klie, MD, MA, FASAM; Addiction Medicine Fellowship Program Director and Associate Professor of Family Medicine, University of Colorado Anschutz Medical Campus

Non-faculty contributors and others involved in the planning, development and editing/review of the content have no relevant financial relationships to disclose with ineligible companies.*

*Ineligible companies – Companies whose primary business is producing, marketing, selling, re-selling or distributing healthcare products used by or on patients.

Accreditation:

The HCA Healthcare Continental Division is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. 

Credit Designation:

The HCA Healthcare Continental Division designates this live activity for a maximum of 1.0 AMA PRA Category 1^TM.  Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Commercial Support:  

This Activity was developed without support from any ineligible company.*The ACCME defines ineligible companies as those whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. Note: The ACCME does not consider providers of clinical service directly to patients to be commercial interests – unless the provider of clinical services is owned, or controlled by, and ACCME defined ineligible company.

Disclosure: 

The HCA Healthcare Continental Division is committed to providing CME that is balanced, objective, and evidenced-based. In accordance with the Accreditation Council for Continuing Medical Education Standards for Integrity and Independence all parties involved in content development are required to disclose all conflicts of interest with ACCME defined ineligible companies. The HCA Healthcare Continental Division has identified, reviewed, and mitigated all conflicts of interest that speakers, authors, course directors, planners, peer reviewers, or relevant staff disclose prior to the delivery of any educational activity. The CME planning committee who are in a position to control the content of this CME Activity, have no relevant financial relationships with ineligible companies to disclose.